Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030303 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by UConn Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00030303 is a Phase 1 study that has completed, run by UConn Health. The registered enrollment target is 20 participants.
The verdict
NCT00030303, a Phase 1 study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.
Interventions
- BIOLOGICAL recombinant 70-kD heat-shock protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2001-01 |
| Est. Completion | 2004-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030303
The ClinicalTrials.gov registry entry for NCT00030303 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant 70-kD heat-shock protein is the first listed.
NCT00030303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030303 about?
NCT00030303 is a clinical study titled "Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia". RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.
What is the current status of trial NCT00030303?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2001-01. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00030303?
The interventions under investigation include: recombinant 70-kD heat-shock protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00030303?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.